Through internal discovery efforts and partnerships, our goal is to discover, develop and commercialize novel AOC therapeutics that overcome current barriers to the delivery of oligonucleotides and unlock their potential to treat a wide range of serious diseases currently lacking adequate treatment options. 

We continue to broaden the reach of AOCs with our advancing and expanding pipeline pursuing additional programs that expand our AOC pipeline beyond muscle and into other indications including cardiology and immunology. 

We have one rare precision cardiology program in lead optimization and in November 2023 we announced a global licensing and research collaboration with Bristol Myers Squibb focused on the discovery, development and commercialization of multiple cardiovascular targets. 

By identifying and optimizing antibodies for specific immune cell types, our goal is to leverage our AOC platform to develop product candidates that can deliver siRNAs to disease-driving subsets of immune cells. We are collaborating with Eli Lilly and Company initially on 6 mRNA targets in immunology and other select indications outside of muscle for the delivery, development and commercialization of AOCs.